Clinical trial NCT05929092 - References

Hematopoietic Stem Cell Transplantation — TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases

Citation(s)

•   Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC
  Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. Cancer Discov. 2021 Apr;11(4):874-899. doi: 10.1158/2159-8290.CD-20-1638.
•   Auberger P, Tamburini-Bonnefoy J, Puissant A
  Drug Resistance in Hematological Malignancies. Int J Mol Sci. 2020 Aug 24;21(17):6091. doi: 10.3390/ijms21176091.
•   Ehrhart J, Sanberg PR, Garbuzova-Davis S
  Plasma derived from human umbilical cord blood: Potential cell-additive or cell-substitute therapeutic for neurodegenerative diseases. J Cell Mol Med. 2018 Dec;22(12):6157-6166. doi: 10.1111/jcmm.13898. Epub 2018 Oct 18.
•   Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR
  Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 Aug 6;136(6):674-683. doi: 10.1182/blood.2019004143.
•   Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, et al
  Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989 Oct 26;321(17):1174-8. doi: 10.1056/NEJM198910263211707. No abstract available.
•   Hellmich C, Moore JA, Bowles KM, Rushworth SA
  Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Front Oncol. 2020 Feb 25;10:230. doi: 10.3389/fonc.2020.00230. eCollection 2020.
•   Hu D, Gao YH, Yao XS, Gao H
  Recent advances in dissecting the demethylation reactions in natural product biosynthesis. Curr Opin Chem Biol. 2020 Dec;59:47-53. doi: 10.1016/j.cbpa.2020.04.014. Epub 2020 May 24.
•   Hu D, Yuan S, Zhong J, Liu Z, Wang Y, Liu L, Li J, Wen F, Liu J, Zhang J
  Cellular senescence and hematological malignancies: From pathogenesis to therapeutics. Pharmacol Ther. 2021 Jul;223:107817. doi: 10.1016/j.pharmthera.2021.107817. Epub 2021 Feb 12.
•   O'Donnell JS, Teng MWL, Smyth MJ
  Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi: 10.1038/s41571-018-0142-8.
•   Rambaldi A, Grassi A, Masciulli A, Boschini C, Mico MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scime R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A
  Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.
•   Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L
  Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 May 1;18(5):599-634. doi: 10.6004/jnccn.2020.0021.
•   Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, Olson A
  Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med. 2023 Mar 3;12(2):55-71. doi: 10.1093/stcltm/szac086.
•   Sun HP, Zhang X, Chen XH, Zhang C, Gao L, Feng YM, Peng XG, Gao L
  Human umbilical cord blood-derived stromal cells are superior to human umbilical cord blood-derived mesenchymal stem cells in inducing myeloid lineage differentiation in vitro. Stem Cells Dev. 2012 Jun 10;21(9):1429-40. doi: 10.1089/scd.2011.0348. Epub 2011 Dec 5.
•   Yang G, Wang X, Huang S, Huang R, Wei J, Wang X, Zhang X
  Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy. Front Immunol. 2022 Oct 4;13:1034438. doi: 10.3389/fimmu.2022.1034438. eCollection 2022.
•   Zheng CC, Zhu XY, Tang BL, Zhang XH, Zhang L, Geng LQ, Liu HL, Sun ZM
  Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML. Bone Marrow Transplant. 2017 Jan;52(1):88-94. doi: 10.1038/bmt.2016.182. Epub 2016 Jul 4.

Total Body Irradiation/ Fludarabine/ Busulfan/ Cyclophosphamide (TFBC) Combined With Umbilical Cord Blood Transplantation (UCBT) in the Treatment of High-risk Malignant Hematological Diseases

Details for clinical trial NCT05929092